葛根素对比丹参治疗椎-基底动脉供血不足的Meta分析

目的:评价葛根素对比丹参治疗椎-基底动脉供血不足(VBI)的临床疗效和安全性。方法:计算机检索Medline、EM-Base、CBM、CNKI、VIP、万方数据库以及Cochrane图书馆,纳入葛根素对比丹参治疗VBI的随机对照试验(RCT),对纳入研究进行质量评价和Meta分析。结果:共纳入16个RCT,1 043例VBI患者,文献质量都为C级;分析结果显示,葛根素总有效率高于丹参,差异有统计学意义,相对危险度(RR)=1.17,95%可信区间(CI)(1.11,1.23);葛根素改善左、右椎动脉血流速度和基底动脉血流速度也优于丹参,差异有统计学意义,均数差(WMD)(95%CI)分别为3.15(1.50,4.79)、3.20(1.39,5.02)和4.27(2.07,6.46)。结论:基于当期证据,治疗VBI,葛根素疗效优于丹参。

Meta-analysis of Puerarin Versus Salvia Miltiorrhiza for Vertebrobasilar Insufficiency

OBJECTIVE：To evaluate clinical efficacy and safety of puerarin vs.Salvia miltiorrhiza for vertebrobasilar insufficiency（VBI.） METHODS：Retrieved from Medline,EMBase,CBM,CNKI,VIP,Wanfang Database and Cochrane Library,randomized controlled trials（RCT）on puerarin vs.Salvia miltiorrhiza for VBI were included for quality analysis and metaanalysis.RESULTS：16 RCTs and 1 043 VBI were enrolled and the quality was C class.Metaanalysis indicated that the total effective rate of puerarin is higher than S.miltiorrhiza,there was significant difference between 2 groups（RR=1.17,95%CI（1.11,1.23）.） The velocity in left and right vertebral artery and in basilar artery of puerarin are better than S.miltiorrhizat,here were significant different（WMD（95%CI）：3.15（1.50,4.79）,3.20（1.39,5.02）and 4.27（2.07,6.46）.） CONCLUSION：Based on recent evidence,puerarin is better than S.miltiorrhiza in the treatment of VBI.